Relieve the urgent need of patients with tumor osteomalacia: the innovative drug brosoyuumab prescribes Shanghai's first prescription

(Health Times reporter Yin Wei) On November 24, 2021, brosoyuumab, an innovative targeted therapy for rare diseases, was prescribed by Professor Zhang Zhenlin, the director of the Osteoporosis and Osteopathy Specialist, at the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University.

"We are now paying more attention to calcium deficiency, but phosphorus deficiency is not enough, because there are no obvious symptoms in the early stage of phosphorus deficiency, and once it is discovered that the skeleton is damaged, it even leads to severe disability

Tumor osteomalacia (TIO) is a rare disease of bone mineralization disorder caused by certain tumors that secrete fibroblast growth factor 23 (FGF23).

Professor Zhang Zhenlin introduced that due to the non-specific signs and symptoms of patients, up to 95% of patients may be misdiagnosed initially, and data shows that the time from the onset of symptoms to the diagnosis of patients can range from 2.

"It only took less than a year for brozoyuumab to get rapid approval, expand its indications, to TIO, and then to the head of the country and Shanghai.